Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

Abstract: A method of healing an external wound involves applying an external wound-healing agent to an external wound, or bringing the external wound-healing agent applied to a substrate into contact with an external wound, wherein the external wound-healing agent includes, as an active ingredient, at least one compound of a glycerol alkyl ester represented by defined Formula (I) or a diglycerol alkyl ester represented by defined Formula (II). In a further embodiment, the method involves bringing a fiber aggregate or a film into contact with an external wound, wherein the fiber aggregate or the film each includes a thermoplastic resin and at least one compound of the glycerol alkyl ester or the diglycerol alkyl ester.

Abstract: A wound dressing material comprising a solid substrate having interstitial spaces therein, wherein said substrate is a hydrophilic open-cell foam material, and wherein said interstitial spaces are at least partially filled by a hydrophilic polyurethane foam different from said substrate foam material. Also provided is a method of making a porous wound dressing material comprising the steps of: providing a substrate of a solid hydrophilic first foam material; applying a fluid or gel polyurethane foam prepolymer mixture to at least one surface of said solid substrate; and curing said prepolymer in contact with said solid substrate.

Abstract: The invention herein relates to a wound dressing product, combining a hydrophobic fabric, which is to be placed towards the wound, and is capable of binding unwanted microorganisms, and a moisture carrying matrix such as a gel or a foam. The product of the invention is ideal for treatment of drier wounds. It protects the wound and reduces the number of pathogenic microorganisms, without using antimicrobial substances and at the same time adds or traps moisture to the wound both supporting the hydrophobic functioning of the pad and healing in general by keeping the wound moist.

Abstract: A wound dressing having a perforated material including through-holes. The perforated material having a first and second face. A low adhesive resin coating at least the first face of the perforated material without closing the through holes. The perforated material is a knitted fabric or a woven fabric formed of a multifilament. The perforated material has an average opening area of the through-holes of 0.02 to 1.2 mm2 and an average number of through-holes of 40 to 220 cm?2.

Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

Abstract: The subject of the present invention is a composite wound packing material comprising a casing enclosing a material, or an assembly of materials, forming fluid flow channels, said casing being composed of a self-supporting interface material formed from a thin layer of a composition comprising a hydrophobic matrix and comprising through-holes, said hydrophobic matrix comprising, per 100 parts by weight of a styrene/saturated olefin/styrene triblock copolymer having a viscosity of between 0.2 and 2 Pa·s, as measured in a 10% (weight/weight) solution in toluene, from 400 to 1220 parts by weight of a plasticizer, preferably a plasticizing oil, and from 0 to 720 parts by weight of petroleum jelly, it being specified, moreover, that the total amount of plasticizer and petroleum jelly is greater than or equal to 750 parts by weight and the amount of petroleum jelly is between 400 and 720 parts by weight when the amount of plasticizer is between 1000 and 1220 parts by weight.

Abstract: A method and a system comprise receiving an amount of a first disinfecting solution on and around a wound. An amount of a second disinfecting solution is received on and around the wound. An amount of a third disinfecting solution is received on and around the wound. An amount of a fourth disinfecting solution is received around the wound. Cold laser emissions are received on and around the wound. The cold laser emissions comprise at least multiple wavelengths. A sterile gauze bandage and wrap cover the wound.

Abstract: A system that may be adapted to distribute reduced pressure to a tissue site may include a dressing and a sealing member. The dressing may include a manifold layer, a storage layer, and a plurality of retainers. The manifold layer may be adapted to be positioned proximate the tissue site, and the storage layer may be positioned proximate the manifold layer. The plurality of retainers may be disposed in the storage layer. Each of the retainers may define a fluid communication channel through the storage layer. The retainers may be adapted to substantially preclude deformation of the storage layer into the fluid communication channels. The sealing member may be adapted to cover the dressing and to provide a fluid seal between the sealing member and the tissue site.

Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

Abstract: A method of treating scar tissue by applying a composite sheet for delivering therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Microchannels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of about 0 to about 30 days.

Abstract: A dressing for covering a wound. The dressing including: a first component having a first shape with a first dimension; a second component releasably attached to a first surface of the first component to maintain the first component in a second shape different from the first shape, the second shape having a second dimension longer than the first dimension; and an adhesive disposed on a surface of the first component different from the first surface for attaching the first component to the wound such that the second component can be released from the first component to allow the first component to take the first shape to apply a pressure to portions of the skin surrounding the wound to close the wound. Wherein the first and second dimensions are a length in more than one direction.

Abstract: A method of manufacturing a wound dressing or the like comprises the steps of a) providing a layer of substrate material; b) extruding a curable hydrophobic gel precursor composition onto that substrate material via one or more mobile applicators; and c) causing or allowing the hydrophobic gel precursor composition to cure to form a hydrophobic gel. Wound dressings or the like that can be manufactured by such a method comprise a layer of substrate material, the wound facing surface of which carries bands of hydrophobic gel that are intermingled in a lattice-like arrangement.

Abstract: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Abstract: A bandage includes a reservoir filled with a perfluorochemical fluid, saturated with oxygen. Oxygen passes through a permeable membrane to the skin or wound to promote healing, and carbon dioxide travels from the skin or wound to the reservoir.

Abstract: The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.

Abstract: The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: Described are hemostasis devices useful for implantation in biopsy tracts, which device comprise highly compact, dried hemostatic sponge elements. Preferred devices also include compacted sponge matrices exhibiting high density and rigidity in combination with high volumetric expandability when wetted. Also described are methods for making and using such devices.

Abstract: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.

Abstract: Described are pharmacological compositions comprising a gum resin; a pharmacologically active agent and a topically acceptable volatile solvent for the gum resin and active agent. Also described are methods for the transdermal or transmucosal delivery of a pharmacologically active agent using such compositions.

Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.

Abstract: A medical dressing comprising a complex of silver and being capable of releasing antimicrobial silver ion activity, said complex comprising silver and a transition element of Group IV of the periodic system of elements enables a controlled release of silver ion activity to a wound bed.

Abstract: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.

Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.

Abstract: A wound care device for local treatment of pain in a wound is provided. The device comprises an active pain relieving composition, which can also be an anti-inflammatory agent. The wound care device is suitable for treatment of pain in open wounds. The device can include small amounts of pain relieving compositions that are effective in relieving pain at the wound while not resulting in any systemic effects. The device may be in the form of a wound dressing, and the pain relieving composition may be delivered to the wound through a controlled release system.

Abstract: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Abstract: An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid.

Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.

Abstract: A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof. In use, the surface having the depressions is disposed adjacent a surface of the wound. A method of manufacturing a therapeutic device for promoting the healing of a wound in a mammal comprising the steps of providing a permeable substrate, and forming a plurality of depressions into a surface of the permeable substrate to provide the therapeutic device. A method of treating a wound comprises: providing a permeable structure comprising a plurality of randomly disposed fibers and having i) a plurality of wound surface contact elements disposed between end portions of the structure, and ii) a plurality of voids defined by the contact elements; and applying the permeable structure to at least one surface of the wound.

Abstract: The present invention comprises methods and compositions for delivery devices. More particularly, the present invention comprises methods and compositions for devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having oxygen and optionally active agents incorporated therein. The matrix may be formed into any desired shape for treatment of compromised tissue or for delivery of oxygen to a localized environment.

Abstract: The present invention relates to a hemostatic dressing which comprises a plurality of layers that contain resorbable materials and/or coagulation proteins. In particular, the invention includes dressings in which a layer of thrombin is sandwiched between a first and second layer of fibrinogen and wherein the layer of thrombin is not coextensive with the first and/or second layer of fibrinogen. The hemostatic dressings are useful for the treatment of wounded tissue.

Abstract: The present invention discloses a class of compounds which have an enhancing effect on peroxidase based antimicrobial compositions. The invention relates to pharmaceutical compositions for prolonged topical use comprising enhancing agents such as methoxyphenols and substituted benzylaldehydes. Examples hereof are respectively guaiacol and vanillin.

Abstract: Compositions and methods for sealing, coating and adhering tissues are provided that utilize a polymeric system comprising at least a Polymer and a crosslinking agent; and, optionally, (i) a Gelation Disrupting Agent, (ii) an Augmentative Polymer or Monomer, (iii) an Adjunct Compound (iv) an Antimicrobial Agent (v) an Adhesion Enhancer, (vi) a Crosslink Augmentating Agent or any combination thereof. Additionally, a Therapeutic Agent may be incorporated.

Abstract: The described invention provides compositions, dressings and methods for treating a cutaneous scar in a subject. The compositions of the derived invention contains a pharmaceutical composition comprising a therapeutic amount of a Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) inhibitor comprising an MK2 polypeptide inhibitor or a functional equivalent thereof, and a pharmaceutically acceptable carrier.

Abstract: The invention provides wound dressings comprising an absorbent (porous) hydrogel composition comprising a foam portion which comprises a flexible plasticized hydrophilic polymer matrix having an internal cellular structure, and a continuous portion which comprises a flexible plasticized hydrophilic polymer matrix having relatively continuous internal structure. The continuous portion of the hydrogel composition includes apertures providing fluid flow communication through the continuous portion between an external surface of the continuous portion and the foam portion whereby the foam portion can take up external water or other fluid into the cellular structure through the apertures of the continuous portion. The continuous portion of the hydrogel composition may be tacky to the skin, allowing its use as a bioadhesive.

Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.

Abstract: A pharmaceutical composition and method for topical wound treatment by topical treatment with gallium salts, preferably gallium nitrate. In a preferred embodiment, the gallium nitrate is in an aqueous form without coagulation inhibitors such as citrate. The aqueous gallium salt formulation may be administered by a variety of methods including spraying, topical lotions, topical foams, and/or bandages containing or packaged with breakable ampoules of aqueous gallium salt formulations, and liquid bandage formulations. The aqueous gallium salt formulation may additionally contain other active and inactive ingredients, such as viscosity modifying agents, foaming agents, antiseptics, antibiotics, enzymes, fibrinogen, fibrin, polymers and growth factors.

Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.

Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.

Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.

Abstract: A dressing for covering a wound in which the dressing includes: a first component having a first shape with a first dimension; a second component releasably attached to a first surface of the first component to maintain the first component in a second shape different from the first shape, the second shape having a second dimension longer than the first dimension; and an adhesive disposed on a surface of the first component different from the first surface for attaching the first component to the wound such that the second component can be released from the first component to allow the first component to take the first shape to apply a pressure to portions of the skin surrounding the wound to close the wound.

Abstract: A treated substrate with improved availability of a beneficial component for transfer to a target surface and methods for making the same are described. The substrate has a contacting surface with a beneficial component that is transferred from the contacting surface to a target surface during use of the article. The beneficial component is applied to the article in such a way as to “Top-Bias” the component on or near the contacting surface of the article.

Abstract: A smart antimicrobial material and dressing to inhibit microbial growth is provided. Endogenous chemicals, such as metabolites produced from bacteria are utilized as chemical substrates and converted by enzymes to produce a disinfecting compound that will in turn inhibit the targeted microorganism. The material shall remain passive until such time as it encounters a microbe which expresses and/or secretes specific metabolites or markers. The enzyme or enzymes embedded in the smart material converts the metabolite into a disinfecting compound, which in turn either kills the microorganism or prevents it from multiplying on the surface of the material.

Abstract: The present invention is directed to recombinant fibronectin peptide mimetics and wound healing compositions containing the same. Other aspects of the present invention include wound healing dressings that comprise the wound healing composition of the present invention and a wound dressing material and methods of treating wounds using these compositions.

Abstract: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

Abstract: A flow directing material includes a substrate. The substrate includes a first region that exudes fluid under a compressive or tensile load and a second region that imbibes fluid under the compressive or tensile load. The first region has a first porosity and a first permeability and the second region has a second porosity and a second permeability. The first permeability and the second permeability are about 10?13 m2 to 105 m2. The first porosity and the second porosity are about 0.3 to about 0.7. The first porosity and the second porosity are at least about 5% different.